Ask Lazlo

life sciences… only

Tarceva Reaches Phase III Primary Endpoint

A press release yesterday from Genentech (DNA) reports that its drug Tarceva (erlotinib) reached its primary endpoint in a Phase III global clinical trial.  Tarceva is used to treat non-small cell lung cancer (NSCLC) and functions by interrupting the tyrosine kinase activity of epidermal growth factor receptor (EGFR).

The study demonstrated that treatment with Tarceva immediately following platinum-based chemotherapy increased the period of time without further disease progression in patients suffering from NSCLC.  

Tarceva was initially discovered by OSI Pharmaceuticals (OSI) and is the only EGFR inhibitor that that has been proven to increase survival rates in advanced NSCLC.  The drug is now marketed through a partnership between OSI and Genentech.


November 7, 2008 Posted by | Biotech | , , , , , , | Leave a comment